Earnings Outlook For UroGen Pharma
Portfolio Pulse from Benzinga Insights
UroGen Pharma (NASDAQ:URGN) is scheduled to release its quarterly earnings report on March 14, 2024, with analysts expecting an EPS of $-0.68. The company's past performance shows a mixed reaction to earnings reports, with the stock price fluctuating based on actual EPS versus estimates and subsequent guidance. Over the last year, URGN shares have increased by 85.85%, indicating a positive outlook from long-term shareholders.
March 13, 2024 | 6:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
UroGen Pharma is expected to report an EPS of $-0.68 for the upcoming quarter. Historical data shows variable stock price reactions to earnings reports and guidance. Shares have seen significant growth over the past year.
The expected EPS and historical performance suggest a cautious outlook. While past earnings have led to mixed stock reactions, the overall yearly growth is positive. The actual impact will depend on whether URGN meets or exceeds the EPS estimate and the forward guidance provided.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100